Fig. 4

BrdU-labelling identifies early proliferating oligodendrocyte lineage cells. a Experimental setup of BrdU injections from 12 h until 3 d post-correction. Tissue was harvested at 4, 7, 14 and 21 dpc, as indicated by red arrows. b, c Immunofluorescence double labeling of BrdU/Olig2 double-positive cells (arrowheads) in a control animal (b) and the striatal ODS lesion area at 4 dpc (c). BrdU = green, Olig2 = red, DAPI = blue, magnification × 400, scale bar 50 µm. d-e NG2/BrdU immunofluorescence double labeling in the lesion 7 (d) or 14 dpc (e). BrdU = purple, NG2 = white, DAPI = blue, magnification × 400, scale bar 20 µm. f, g Quantification of cellular densities of NG2 + OPCs (f) and mature TPPP/p25+ oligodendrocytes with and without BrdU immunoreactivity at different time points inside the lesion. Black bars = BrdU+ cells, white bars = BrdU⁻ cells (mean ± SEM, two-way ANOVA and Tukey’s multiple comparison, ***p < 0.001). h Mature TPPP/p25+ oligodendrocytes are widely BrdU-negative at 21 dpc (TPPP/p25 = red, BrdU = green, magnification × 200, scale bar 50 µm)